Bone health is the key to the overall well -being, but millions of diseases will weaken bones, lead to pain, fractures and quality of life decline. Although the current treatment is mainly focused on preventing further bone loss, breakthrough discovery is not only expected to stop this deterioration, but also can actively promote bone growth. Entering Pepitem, this is a natural peptide with unique abilities that can stimulate new and stronger bones and prevent bone crash. This dual action method can completely change how we treat common osteoporosis and arthritis and other common osteo diseases, thereby providing new hope for patients around the world.
Researchers at the University of Birmingham, led by Professor Helen McGettrick, explored major progress in bone health by exploring a new type of peptide called Pepitem. Their work was published in the medical report, revealing how Pepitem stimulates bone growth and helps prevent bone loss, thereby providing new hope for the treatment of various bone -related diseases.
Professor Mcgettrick and her team, including Dr. Jonathan Lewis, Dr. Amy Naylor, Dr. James Edwards and Kathryn Frost, are committed to understanding how Pepitem enhances bone repair. With the age of the crowd, effective treatment is needed to fight bone degeneration (such as osteoporosis) becoming more and more important. This study provides a new perspective for managing bone health, changing Pepitem as the potential game rules at the scene.
Studies have found that PEPITEM can significantly enhance the activity of osteocytes, enable cells responsible for the formation of new bone to reduce the activity of osteocytes, thereby destroying bone tissue. This dual action is particularly important because it not only supports new bone formation, but also helps to prevent bone loss. This is a key combination of maintaining bone strength and health. Given that the treatment of skeletal diseases currently involves slowing down bone loss or the formation of bones, the completion ability of Pepitem may represent a significant improvement in existing therapy.
In order to observe the influence of PEPITEM, researchers use advanced modeling technology, which indicates that peptide can increase bone density is the key indicator of bone health. Bone density is the quality of bone minerals in the finger tissue, which determines the strength and durability of the bones. Professor McGettrick emphasized the importance of these results and pointed out: “Our research shows that Pepitem may significantly improve bone repair and prevent bone loss, which may enhance the quality of life of patients with bone diseases.”
In addition to repair, PEPITEM can also be used as preventive treatment, especially for people who have a huge risk of bone density loss due to aging or chronic diseases. It promotes osteosocyte activity while inhibiting the ability of osteocytes to make it a promising choice for maintaining bone health.
Looking forward to the future, the research team plans to conduct further research to better understand the long -term impact of Pepitem and explore its potential in the clinical environment. “The next step is to bring our discovery into clinical practice.” “We hope that Pepitem will become a key factor in bone health treatment in the near future.”
In short, PEPITEM, as the development of therapeutic agents, represents a significant improvement of skeletal disease treatment. By supporting bone formation and preventing bone loss, PEPITEM can play a vital role in managing bone health, providing new hope for people affected by bone disease.
Journal reference
Lewis JW, FROST K, Neag G, etc. “Treatment pathway in bone repair: uses synthetic metabolic bone peptides to enhance bone growth and prevent bone loss.” Cell reported drugs. 2024. Doi: https: //doi.org/10.1016/j.xcrm.2024.101574
About the author
As an experimental biologist with more than 18 years of research experience, Professor Helen McGettrick Her inflammation in health and diseases, the innovation and unique research of blood vessels and matrix biology, have obtained recognized international reputation, especially using innovative experiments to further understand our understanding of important clinical diseases. She led the inflammation, blood vessels and bone research teams of the University of Birmingham. Together with her team, she developed a novel 3D multi -cell multi -layer work set in vitro Model (co -cultivation, organ, organ/organization on the film), and Prelude Patient sample analysis, pre -clinical models of diseases and big data, to study the cells and molecular mechanisms for inflammation and tissue repair, and observe these discoveries into patients. Her team is currently seeking to expand our understanding of stress events (such as inflammation, age, surgery, disease, obesity) of stress events, and develop innovative biomarkers and/or therapeutics Solve the fragile event induced by the “pressure incident”. population.
Jonathan Lewis He is a doctoral researcher at the University of Birmingham. He has a doctorate degree in the University of Birmingham, explores bones in the state of health and disease, and cope with treatment medicines. Dr. Amy Naylor’s supervision. His doctorate is funded by the Medical Research Commission and the Center for Bone Bone Agenus (CMAR). Jonathan is currently exploring changes in multiple human systems (such as immunity, muscles and fats) during aging, responding to pressure source incidents, and studying bone stability through new organ models.
Amy Naylor He is an associate professor at the University of Birmingham. She completed a PhD in skeletal development at the University of Newcastle University in the United Kingdom, and has since been committed to studying bone formation during the inflammation and the entire life process. The importance of this work has been recognized by the form of two personal research golds of charitable and arthritis. With the help of NC3RS and EPSRC funds, Amy has developed in vitro The research of skeletal organ models is prioritized. She is committed to spreading and collaboration with other research teams to increase the absorption of this method.
James Edwardz Lead the aging and regeneration research team of the University of Oxford. This work reveals the reasons for the decline in aging in multiple organizations and discuss a new method of better treatment of aging.
Based on the background of muscle skeletal science and skeletal biology, James focuses on the ruthless connection between aging and life factors and life factors, as well as the onset and progress of elderly diseases, including osteophyte loss and arthritis. Essence These include studying how acetylization and functions of Sirtuin biology in muscle skeletal tissue and key cell proteins are regularly regulated with aging. Can activate arthritis to activate arthritis. Diseases, as well as how new degradable alloys improve fracture healing and bone repair. This work has shown that how to use naturally existing products (such as poar and polyphenol) targeted aging mechanisms, which has a direct and significant effect on the aging mechanism to retain normal cell biology and tissue structures, and can be with age Growth and prevent the attack of the disease.
The recent work has developed a comprehensive cell, genomic and protein group, which is used to evaluate novel and re -use drugs, and reveals good tolerance and established diseases related to age (such as cardiovascular diseases) related to age (such as cardiovascular disease) New indications for drugs.
Kathryn Frost: I am a doctoral student in the last year. The impact of the new type of therapy of the Birmingham University Translation Inflammation Research Center on age -related skeletal diseases. My graduate career began at the neuroscience of the University of Nottingham, where I investigated the back -to -side changes related to age during postpartum development. This exacerbates my interest in age -related complex biological systems, and has led to my current project focusing on reducing bone loss and promoting bones in the disease to reshape. After the doctoral degree is completed, I will move to Porto University, where I will combine interest and study the interaction of the nervous system and skeletal system.
